Two biomarkers predict immunotherapy response for NSCLC



Two biomarkers were correlated with poor outcomes for patients with non–small cell lung cancer (NSCLC) who were treated with immune checkpoint inhibitors, according to the results of a multicenter retrospective study.

SOURCE: Mezquita L et al. Jama Oncol. 2018 Jan 11. doi: 10.1001/jamaoncol.2017.4771.


Oncology Practice CHEST Physician


Immunotherapy Lung Cancer

Article Type